Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)

Inclusion Criteria: * Patients who have given their written consent to participate in this study * Patients who are 20 years of age or older at the time of consent (regardless of gender) * Patients with type 2 diabetes mellitus * Patients with chronic kidney disease who meet both of the following criteria; i) eGFR greater than 25 mL/min/1.73 m2 and less than 90 mL/min/1.73 m2, ii) UACR greater than 30 mg/g.cr. and less than 3500 mg/g.cr. * Patients who have not changed their medications for type 2 diabetes and chronic kidney disease in the past 4 weeks prior to obtaining consent Exclusion Criteria: * Patients who are currently taking or have taken MRAs containing finerenone in the past 4 weeks prior to obtaining consent. * Patients with a history of hypersensitivity to finerenone * Patients with HbA1c greater than 10%. * Patients with a serum potassium level of 4.9 mEq/L or higher * Patients with NYHA class II-IV HFrEF (LVEF \<35%) * Patients with poorly controlled hypertension (e.g., systolic BP \>170 mmHg, diastolic BP \>110 mmHg, or hypertensive emergencies) * Patients with a history of ischemic stroke, acute coronary syndrome, cardiovascular surgery or percutaneous intervention, or hospitalization for worsening heart or renal failure in the past 8 weeks prior to obtaining consent * Patients with a preplanned surgical or percutaneous intervention for coronary artery reconstruction or other cardiovascular disease during the individual observation period. * Patients with a preplanned treatment such as electrical cardioversion, cardiac resynchronization therapy or pacemaker implantation during the individual observation period. * Patients with preplanned dialysis or kidney transplantation during the individual observation period. * Patients with severe hepatic dysfunction (Child-Pugh Class C) * Patients receiving itraconazole, ritonavir-containing products, atazanavir, darunavir, fosamprenavir, cobicistat-containing products, or clarithromycin, or ensitrelvir * Patients with Addison's disease * Patients with active infectious diseases * Pregnant, possibly pregnant, or lactating patients * Other patients deemed inappropriate for this study by the principal investigator or subinvestigators (e.g., patients with renal artery stenosis, one kidney, or active malignancy).